Entrada Therapeutics Inc TRDA 深 沪
等待开盘 06-26 09:30:00 美东时间
7.11
-0.430
-5.70%
华盛通- 最 高7.71
- 今 开7.55
- 成交量 21.37万股
- 最 低 6.845
- 昨 收 7.54
- 总市值 2.01亿
- 52周最高 16.45
- 市盈率 静 --
- 换手率 0.75%
- 52周最低 4.93
- 委 比 88.62%
- 总股本 2831.24万
- 历史最高 36.85
- 量 比 0.97
- 振 幅 11.47%
- 历史最低 1.10
- 每 手 1
- 风险率 2.83%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Dow Dips 350 Points; US Foods Posts Downbeat Earnings
Dow falls over 100 points, S&P 500 and NASDAQ also down. Tech sector up, energy stocks down. US Foods reports lower Q1 earnings and sales. Agilon Health, Aaon, and Rackspace Technology see gains while Entrada, Fastly, and enGene Therapeutics decline. Euro zone and Asian markets mixed.
05-08 01:39
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
Entrada Therapeutics appoints Dr. Maha Radhakrishnan to its Board of Directors to leverage her expertise in drug development, particularly for advancing Duchenne muscular dystrophy programs into clinical trials. Dr. Radhakrishnan brings extensive experience from roles at Sofinnova Investments, Biogen, and Sanofi, and her leadership will support Entrada’s innovative intracellular therapies.
2025-06-03 11:00
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Entrada Therapeutics granted 23,820 RSUs to six new employees under its 2025 Inducement Equity Plan, effective June 1, 2025. The RSUs vest over time, with 25% vesting after one year and 6.25% quarterly thereafter. The Company, a clinical-stage biopharmaceutical firm, focuses on developing medicines for intracellular targets, including treatments for neuromuscular and ocular diseases.
2025-06-02 20:30
Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
Entrada Therapeutics secures EU authorization for ELEVATE-45-201, a Phase 1/2 study of ENTR-601-45 for Duchenne muscular dystrophy patients amenable to exon 45 skipping. The study aims to assess safety, tolerability, and efficacy, with initiation planned for Q3 2025. ENTR-601-45 is an exon-skipping therapy designed to restore dystrophin production, addressing a significant unmet need in this DMD subpopulation.
2025-05-28 11:00
Oppenheimer Reiterates Outperform on Entrada Therapeutics, Maintains $25 Price Target
Oppenheimer analyst Francois Brisebois reiterates Entrada Therapeutics (NASDAQ:TRDA) with a Outperform and maintains $25 price target.
2024-08-26 22:54
